Related Experiment Videos
Intravenous indomethacin therapy in premature infants with persistent ductus arteriosus--a double-blind controlled
Insights
Intravenous indomethacin effectively treated persistent ductus arteriosus (PDA) in premature infants, reducing the need for ventilation and surgery. While side effects were transient, mortality and bronchopulmonary dysplasia rates remained similar between groups.
Area of Science:
- Neonatalogy
- Pediatric Pharmacology
- Cardiology
Background:
- Persistent ductus arteriosus (PDA) is a common complication in premature infants.
- PDA can lead to significant short- and long-term health issues.
- Current treatment options for PDA have limitations.
Purpose of the Study:
- To evaluate the efficacy and safety of intravenous indomethacin for treating PDA in premature infants.
- To compare indomethacin therapy with placebo in a double-blind controlled trial.
- To assess the impact of indomethacin on respiratory support and surgical intervention needs.
Main Methods:
- A double-blind, placebo-controlled trial involving 55 premature infants with significant PDA.
- Infants received either intravenous indomethacin or placebo around 8.9 days of age.
- Outcomes measured included PDA closure, need for assisted ventilation, surgical closure, side effects, mortality, and bronchopulmonary dysplasia (BPD).
Main Results:
- Indomethacin achieved a significant effect on PDA in 89% of treated infants.
- Indomethacin improved PDA in 86% of infants not showing spontaneous improvement.
- Short-term side effects were transient; no significant differences in mortality or BPD morbidity were observed between groups.
Conclusions:
- Intravenous indomethacin is an effective treatment for PDA in premature infants, with transient side effects.
- Indomethacin therapy reduces the need for assisted ventilation and surgical PDA closure.
- Infants developing BPD had indicators of more severe pulmonary disability at birth.
Abstract:
A double-blind controlled trial of intravenous indomethacin therapy was performed using a group of 55 premature infants (27 placebo, 28 indomethacin) with a significant persistent ductus arteriosus. Indomethacin administration at a mean postnatal age of 8.9 days was followed by a significant effect on PDA in 89%; 75% of successes were attributable to indomethacin and 25% to spontaneous effects, an improvement by indomethacin of 86% in infants not undergoing spontaneous improvement. The short-term side effects of indomethacin were transient; urinary output and serum sodium concentration decreased and serum potassium concentration increased. Indomethacin administration was associated with a decreased need for assisted ventilation and a decreased need for surgical closure of PDA. There was no significant difference between the placebo and indomethacin groups in mortality and bronchopulmonary dysplasia morbidity. The infants who developed BPD had higher RDS scores and lower PO2 values, requiring higher FIO2s within four hours of birth than those who did not develop BPD, indicating a more severe underlying pulmonary disability present birth.